Form 4 for IMNM Immunome Inc.
Accepted 2025-03-26 00:00:00 ET · period of report 2025-03-26 · accession 0001415889-25-009017 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-26 | 2025-03-26 | IMNM | SIEGALL CLAY B | Pres, CEO, Dir | P - Purchase | $7.29 | +137.1K | 806.7K | +20% | +$999.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-26 | P | A | 137,100 | $7.29 | 806,736 | D | — | — | (F1) The weighted average purchase price for the transaction report was $7.29, and the range of prices were between $7.16 and $7.40, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. |